Cargando…
SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F releas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957593/ https://www.ncbi.nlm.nih.gov/pubmed/27163259 http://dx.doi.org/10.1080/15384101.2016.1182267 |
_version_ | 1782444196593926144 |
---|---|
author | Meng, Fengxi Qian, Jiang Yue, Han Li, Xiaofeng Xue, Kang |
author_facet | Meng, Fengxi Qian, Jiang Yue, Han Li, Xiaofeng Xue, Kang |
author_sort | Meng, Fengxi |
collection | PubMed |
description | Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F release and cell cycle progression from G0/G1 to S phase. However, the factors that regulate cyclin-dependent protein kinase (CDK)-dependent hyper-phosphorylation of Rb during the cell cycle remain obscure. In this study, we show that throughout the cell cycle, Rb is specifically small ubiquitin-like modifier (SUMO)ylated at early G1 phase. SUMOylation of Rb stimulates its phosphorylation level by recruiting a SUMO-interaction motif (SIM)-containing kinase CDK2, leading to Rb hyper-phosphorylation and E2F-1 release. In contrast, a SUMO-deficient Rb mutant results in reduced SUMOylation and phosphorylation, weakened CDK2 binding, and attenuated E2F-1 sequestration. Furthermore, we reveal that Rb SUMOylation is required for cell proliferation. Therefore, our study describes a novel mechanism that regulates Rb phosphorylation during cell cycle progression. |
format | Online Article Text |
id | pubmed-4957593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49575932016-08-05 SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase Meng, Fengxi Qian, Jiang Yue, Han Li, Xiaofeng Xue, Kang Cell Cycle Reports Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F release and cell cycle progression from G0/G1 to S phase. However, the factors that regulate cyclin-dependent protein kinase (CDK)-dependent hyper-phosphorylation of Rb during the cell cycle remain obscure. In this study, we show that throughout the cell cycle, Rb is specifically small ubiquitin-like modifier (SUMO)ylated at early G1 phase. SUMOylation of Rb stimulates its phosphorylation level by recruiting a SUMO-interaction motif (SIM)-containing kinase CDK2, leading to Rb hyper-phosphorylation and E2F-1 release. In contrast, a SUMO-deficient Rb mutant results in reduced SUMOylation and phosphorylation, weakened CDK2 binding, and attenuated E2F-1 sequestration. Furthermore, we reveal that Rb SUMOylation is required for cell proliferation. Therefore, our study describes a novel mechanism that regulates Rb phosphorylation during cell cycle progression. Taylor & Francis 2016-05-10 /pmc/articles/PMC4957593/ /pubmed/27163259 http://dx.doi.org/10.1080/15384101.2016.1182267 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Reports Meng, Fengxi Qian, Jiang Yue, Han Li, Xiaofeng Xue, Kang SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title | SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title_full | SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title_fullStr | SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title_full_unstemmed | SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title_short | SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase |
title_sort | sumoylation of rb enhances its binding with cdk2 and phosphorylation at early g1 phase |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957593/ https://www.ncbi.nlm.nih.gov/pubmed/27163259 http://dx.doi.org/10.1080/15384101.2016.1182267 |
work_keys_str_mv | AT mengfengxi sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase AT qianjiang sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase AT yuehan sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase AT lixiaofeng sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase AT xuekang sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase |